RLMD: Relmada Therapeutics, Inc.
About
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in addressing diseases of the central nervous system. It develops esmethadone, an N-methyl-D-aspartate receptor antagonist for the treatment of CNS diseases, and oral agent for depression and other potential indications. The company was founded by Paolo Manfredi on May 31, 2012 and is headquartered in Coral Gables, FL.
Current Value
$2.971 Year Return
Current Value
$2.971 Year Return
Key Details
Market Cap
$89.92M
P/E Ratio
-1.04
1Y Stock Return
1.36%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.9
Strategies that include RLMD
Stock's related to RLMD
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CYTK | 33.26% | $6.03B | +60.96% | 0.00% |
| ATXS | 29.12% | $550.23M | +114.29% | 0.00% |
| SUNS | 26.90% | $105.89M | +35.31% | 1.37% |
| QURE | 26.75% | $283.68M | -13.52% | 0.00% |
| NXT | 26.13% | $5.23B | -7.21% | 0.00% |
| TPST | 25.08% | $37.75M | -77.59% | 0.00% |
| MNST | 23.79% | $52.25B | -1.95% | 0.00% |
| OPK | 22.99% | $1.11B | +7.64% | 0.00% |
| CDLX | 22.20% | $178.39M | -54.00% | 0.00% |
| DLB | 20.71% | $6.76B | -16.58% | 1.69% |
| RAMP | 20.70% | $1.86B | -16.17% | 0.00% |
| LFCR | 20.10% | $261.10M | -4.58% | 0.00% |
| UGP | 19.66% | $3.51B | -35.98% | 3.88% |
| FROG | 19.45% | $3.34B | +11.67% | 0.00% |
| ITCI | 19.22% | $8.84B | +42.41% | 0.00% |
| IRWD | 19.18% | $609.71M | -59.34% | 0.00% |
| RLAY | 19.03% | $803.44M | -39.70% | 0.00% |
| CHRS | 18.72% | $94.65M | -58.72% | 0.00% |
| BMBL | 18.70% | $845.98M | -43.90% | 0.00% |
| AVNS | 18.59% | $818.03M | -16.00% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BANR | -<0.01% | $2.49B | +62.84% | 2.67% |
| SBGI | 0.01% | $1.09B | +17.36% | 6.11% |
| EMBC | -0.01% | $777.82M | -20.98% | 4.49% |
| ACT | -0.01% | $5.21B | +22.57% | 2.11% |
| LSPD | -0.02% | $2.68B | +7.42% | 0.00% |
| CLPT | 0.03% | $302.60M | +84.68% | 0.00% |
| CINF | 0.03% | $23.54B | +48.25% | 2.10% |
| SD | -0.03% | $430.19M | -10.98% | 3.79% |
| RHI | 0.03% | $7.36B | -12.61% | 2.89% |
| COLB | 0.03% | $6.32B | +35.44% | 4.74% |
| STNG | -0.04% | $2.96B | +0.87% | 2.75% |
| LLYVK | 0.04% | $6.24B | +94.65% | 0.00% |
| PETS | 0.05% | $93.60M | -41.21% | 0.00% |
| WF | 0.05% | $8.68B | +19.39% | 7.33% |
| BY | 0.05% | $1.36B | +51.33% | 1.18% |
| CLBK | 0.05% | $1.89B | +4.93% | 0.00% |
| TIPT | -0.06% | $801.52M | +19.70% | 1.11% |
| LKFN | -0.06% | $1.85B | +29.58% | 2.66% |
| URI | -0.06% | $53.89B | +76.13% | 0.79% |
| NNDM | 0.06% | $458.21M | -13.64% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALAB | -22.91% | $15.10B | +164.39% | 0.00% |
| XPEL | -21.27% | $1.18B | -7.73% | 0.00% |
| PAYX | -17.37% | $50.62B | +18.84% | 2.73% |
| SCM | -16.64% | - | - | 11.60% |
| VSAT | -16.41% | $876.93M | -65.78% | 0.00% |
| HELE | -16.32% | $1.53B | -34.86% | 0.00% |
| OCSL | -15.26% | - | - | 14.23% |
| ICUI | -14.89% | $4.15B | +104.38% | 0.00% |
| SLRC | -14.66% | - | - | 10.00% |
| ZCMD | -14.14% | $2.80M | -88.67% | 0.00% |
| NEUE | -13.95% | $40.93M | -34.13% | 0.00% |
| VSTA | -12.96% | $204.94M | -39.33% | 0.00% |
| DOCU | -12.69% | $16.14B | +87.11% | 0.00% |
| KVYO | -12.59% | $9.29B | +24.95% | 0.00% |
| TW | -12.52% | $28.66B | +42.39% | 0.29% |
| SPB | -12.11% | $2.53B | +37.09% | 1.89% |
| WRB | -12.08% | $22.94B | +29.98% | 0.69% |
| BRO | -12.04% | $31.27B | +47.55% | 0.49% |
| SN | -11.93% | $13.84B | +118.64% | 0.00% |
| BYND | -11.71% | $318.19M | -22.91% | 0.00% |
ETF's related to RLMD
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| STPZ | -0.04% | $483.31M | 0.2% |
| CPER | 0.05% | $159.52M | 0.97% |
| CORN | 0.05% | $61.12M | 0.2% |
| EPU | -0.05% | $81.05M | 0.59% |
| IGBH | -0.11% | $93.85M | 0.14% |
| FTSM | -0.12% | $6.08B | 0.45% |
| COMT | 0.17% | $829.06M | 0.48% |
| AMDY | -0.24% | $144.24M | 0.99% |
| GSG | -0.25% | $914.42M | 0.75% |
| SHY | 0.27% | $22.43B | 0.15% |
| SHYD | -0.29% | $311.50M | 0.35% |
| TDTT | 0.30% | $1.84B | 0.18% |
| IBTE | 0.32% | $1.70B | 0.07% |
| VGSH | 0.39% | $19.14B | 0.04% |
| BUG | 0.43% | $783.85M | 0.5% |
| XONE | 0.46% | $548.88M | 0.03% |
| BSCP | -0.47% | $4.05B | 0.1% |
| FLDR | 0.54% | $595.01M | 0.15% |
| IBMM | 0.55% | $391.28M | 0.18% |
| MLPA | 0.55% | $1.64B | 0.45% |
News
Yahoo
Conference being held November 19-21, 2024CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer (CEO), will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Jefferies London Healthcare Conference details: Presentation:Wednesday, November 2
Yahoo
REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight subjects With positive results, Phase 2a proof-of-concept study expected to begin in H1 2025 CORAL GABLES, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announc
Yahoo
Key Takeaways; Cannabis Sector Agrify announced $20 million financing and leadership changes in partnership with Green Thumb Industries TerrAscend reported revenue drop and expanded into Ohio with $10.3 million dispensary acquisition Curaleaf reported $44 million loss in Q3, despite securing a $40 million credit line to support growth Canopy Growth reported revenue drop and continued […]
SeekingAlpha
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call November 7, 2024 4:30 PM ETCompany ParticipantsTim McCarthy - Investor RelationsSergio...
Yahoo
Despite a decrease in cash reserves, Relmada Therapeutics Inc (RLMD) remains focused on pivotal CNS disorder studies with key milestones anticipated by year-end.
Yahoo
Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada", "the Company"), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided a corporate update and announced preliminary and unaudited financial results for the third quarter ended September 30, 2024. The Company will host a conference call today, Thursday, November 7, at 4:30 PM ET.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.